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P R 0 C E E D I N G S 
--ooOoo--
CHAIRMAN TORRES: We are going to open the hearing. I'd 
like to introduce Bob Fredenburg, Chief Consultant to the Taxies 
and Public Safety Committee; to his right is the counsel to the 
Committee, Mr. David Gustafson; and to his right is Patrick Lenz 
who is the Chief Consultant to the Subcommittee No. 3 of the 
Budget health and welfare area. 
I want to thank everyone for joining us this morning, 
and I welcome you to this Joint Hearing of the Senate Budget and 
Fiscal Review Committee. Senator Greene will join us later as 
will other Members of the Legislature as they arrive in the 
Capitol. 
We are having a Joint Committee meeting this morning 
because the problems associated with Proposition 65 
implementation concern both policy and budget. This morning I 
hope we can begin to focus on both. 
The hearing today has two parts. First, the Department 
of Health Services will discuss their policies on the 
identification of cancer causing chemicals. The Department 
released a set of guidelines in November of 1985. I hope we can 
learn what makes good science in evaluating cancer causing 
chemicals as a result of this testimony today. 
The second issue area is the Propos ion 65 
implementation activ s of this administration. The Committees 
are interested in the pol ies which the agencies are following 
as well as the cost associated with those policies. 
2 
The Health and Welfare Agency has been designated the 
2 
lead agency for Proposition 65 implementation. At the beginning 
3 
of this re a Governor's list of 
4 
carcinogens; an outline of an Advisory Committee; and an 
5 
interpretation of some portions of the Initiative. We hope to 
6 
hear from the Agency on all of these areas. 
7 
This Joint Hearing also is the first step of legislative 
8 
action. Working with the budget and public policy together, I 
9 
believe we can move Proposition 65 the fastest way possible. 
10 
We will be havin~ further hearings, and our findings 
1 l 
will be reflected in both budget action and legislation. We hope 
12 
to work with the Administration, business interests, agriculture 
13 
and environmental groups to make Proposition 65 work in 
California. 
14 
First of all, vle to know what we're doing and why 
15 
I 
we're doing I it this State. 
16 
The first tness is morn is Dr. Kelter of the 
17 
18 
Department of Health Serv 11 be talking about s. Dr. Kelter 
the science of the Department's cancer guidelines. I believe 
19 




DR. KELTER: morning, Mr. Chairman. A pleasure to 
22 
be here as always. 
23 
What I'll do the ses of the Committee and to be 
24 
time , we'll outl the Department's gu 1 s primarily as 
25 
regards their purpose and their structure, and then if there are 
26 





The Department began developing these guidelines about 
2 five or six years ago in response to our perceived need to have 
3 some regular established scientific principles for determining 
4 whether or not a chemical should be regarded as a carcinogen. 
5 In addition, we felt it was very important to have 
6 established a set of procedures by which to assess the potency of 
7 carcinogens; that is, are they a strong, powerful carcinogen or 
8 are they very weak, like saccharin, and to have a reliable, 
9 reproducible method for estimating this risk so as to avoid the 
10 " potential for regulatory agencies determining what they wanted a 
l 1 




So in effect, we accomplished that purpose by adopting 
14 
the guidelines in November of 1985, and they are largely based on 
15 
those previously published by the International Agency for 
16 
Research on Cancer, which is abbreviated IARC for short. 
!7 
Risk assessment itself has four major scientific 
18 
activities. The first is hazard identification, and it's this 
19 
process that results in a list. The question being asked in that 
20 




22 I' ~I 
with exposure to this chemical at any dose, if any? And if the 
answer to that question is: In animal studies or in human 
II 







I 26 I, 
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II 
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studies or in laboratory studies of various kinds, the substance 
has been shown by some accepted scientific principles to cause 
mutations or cancer, then the answer to that question is: Yes, 
there is a hazard associated with this chemical and it should be 
subjected to the following three stages in risk assessment. 
I 
4 
The next stage is what's called dose response 
assessment, where some mathematical expression of how strong the 
chemical is for the causing of this effect is evaluated. And 
there are many different ways to do so. Again, the major purpose 
of our guidelines is to establish some baseline methods for 
estimating risk where there are many competing models available, 
and different experimenters and different observers may use 
different methods. We think it's important to have, if you will, 
a recipe which should be used unless there are other extenuating 
circumstances. 
So, the dose response assessment takes a substance which 
has a hazard associated with it and tries to estimate how strong 
an effect this would be. 
The third step is exposure assessment. This is not 
really part of our guidelines at the moment, and at the point 
when the guidelines may be revised, probably the most substantive 
revision would be the inclusion of some aspects of exposure 
assessment. 
If a substance causes cancer and it is very potent but 
nobody's ever exposed to it, then it really doesn't matter. So 
exposure assessment is critical but it's not usually something 
the Department gets into in the risk assessment process. 
CHAIRMAN TORRES: On that point, Dr. Kelter, in the 
forward to the DHS Cancer Guidelines document, it states that the 
document is not regulatory nature is intended to provide 
guidelines for assessing the risks of carcinogenic substances. 
























CHAIRMAN TORRES: Does this document then represent a 
cancer policy of the Department of Health Services? 
5 
DR. KELTER: No, it represents guidelines for performing 
risk assessment for carcinogens. 
CHAIRMAN TORRES: So then we are not dealing with 
policy. We are dealing with guidelines? 
DR~ KELTER: We're dealing with what we called and what 
the National Academy of Sciences has called science policy. 
If the answers to all of our questions about the causes 
of cancer and the effects of chemicals, if those answers were 
known, we wouldn't need science policy. But since they're not 
known, and there are numerous ways to interpret scientific 
information, we have, and other agencies have, agreed that 
written guidelines to help make the scientific judgements 
concerning the results of animal experiments and human studies 
were very important to the process of judging what estimates of 
risk should be like. And that's really the purpose of the 
guidelines -- to establish some a priori principles for the 
interpretation of scientific experiments. 
Cancer policy -- the words "cancer policy" have been 
used over the years, and early on in the development of these 
guidelines, it was anticipated that some regulatory role might 
also be included in the document, but in our final version we 
elected not to do that. 
So they do not have firm regulatory significance, but 
25 
they do contain policy which we and the National Academy call 
26 







~ policy, obviously, would be something along the lines of: 
I; 
Okay, 
so this stuff causes cancer; what are we going to do about it? 
6 
3 None of those "what are we ing to do about it" kinds 
4 of issues are part of the guidelines. The guidelines simply say: 
5 
Does this stuff create a hazard, and how should we assess that 
6 




CHAIRMAN TORRES: Are you comfortable with that? 
9 
DR. KELTER: Sure. Having risk assessment guidelines is 
10 
a great step forward. The California Department and California 
I l 
government were the first to adopt such guidelines as formal 
12 
administrative policy. Subsequently other states and federal 
13 
agencies have more or less done some of the same things. 
14 
Yes, it's a great step forward. I'm very comfortable 
15 
with it. And the subsequent questions of what do we do about it 
16 
continue to be parts of the programs of several areas 
! in DHS. 
17 
1 8 
CHAIRMAN TORRES: So the quest s will be asked what we 
do about them? 
19 
20 
DR. KELTER: Well, they always have been in the context 
21 
of each individual program: taxies, the Hazardous Waste 
22 
Program specifically exists to deal with that question; food and 
23 
drug and drinking water, the same. 
24 
CHAIRMAN TORRES: So, 11 these guidelines be 
25 
applicable to other agenc s as well, like Food and Ag, like the 





DR. KELTER: Well, the guidelines are available for 
2 consideration by any agency and by the Science Advisory Panel for 
' 
Prop. 65, as are the guidelines of other agencies and IARC and 
4 
NTP and EPA. 
5 
CHAIRMAN TORRES: I realize that, but my question is 
6 
more specific than that. 
7 
Will these guidelines be adhered to by other agencies? 
8 
DR. KELTER: That's up to them. The Department's 
9 
guidelines are strictly those of the Department. 
10 
CHAIRMAN TORRES: I'd like to welcome Mr. Seymour and 
II 
Mr. Rosenthal as well. 
12 
Assemblyman Connelly, you're welcome to join us as well. 
13 
DR. KELTER: The fourth and final step in risk 
14 
assessment is what is called risk characterization, and it 
15 




So to review them, the first step is hazard 
identification -- does it or doesn't it cause cancer in animals 
18 
19 
or humans. Secondly, if it does, how potent is it. And thirdly, 
'I 
20 I: i ~ 
is anyone exposed to it. 
I 
I, 
21 I' ,I II 
'I 





So the risk characterization summary step makes a 
statement that under given exposure conditions, exposure to the 
substance would likely cause this number of this kind of effect 
,I 
24 11 li 









I want to reemphasize the fact that a co~ple of issues 
that are prominent in Prop. 65 are not part of the guidelines and 








2 ll q 
3 II 
concepts of risk management, the "what are we going to do about 
it" kinds of questions. As the guidelines are now framed, they 
involve science policy and not publ policy. So, they don't 
4 
include issues like "what are we going to do about it." 
5 
They also do not include issues of definition of 
6 
significant risk. And again, the question of significant risk, 
7 
what is acceptable and what is not acceptable, is not a 
8 
scientific question. It's an issue of public policy, and the 
9 
guidelines do not deal with that either. 
10 
That's all I can say, I think, with regard to an outline 
ll 
of the purposes and content of the guidelines. I'd be happy to 
12 
try and answer any other questions. 
13 
CHAIRMAN TORRES: In light of assertions from what we 
14 
consider scientifically reputable sources, such as the Federal 
15 
Office of Science and Technology, the International Agency for 
Research on Cancer, and the of Health Services' own 
16 
Cancer Guidelines regarding the val ity of using animal data for 
17 
18 
determining human cancer, and the Reagan Administration's 
19 
Office of Science and Technology which recently stated that: 
"It is reasonable to treat an animal 
20 
carcinogen as if it were a human car-
21 
22 
cinogen .... this principle has been 
23 
accepted by all health and regulatory 
24 
agencies and is regarded widely by 
scientists industry and academia as 
25 









Would you please comment on the use of the dat.a for the 
4 
purposes of identifying those chemicals that should have been 
placed on the list and perhaps were not? 
6 
DR. KELTER: Our guidelines by and large say exactly 
7 
what you've just said, that animal data is useful and acceptable 
8 
data for the purposes of identifying substances which may pose a 
9 
cancer threat to humans. And we use animal data, as stated in 
10 
the guidelines, to construct the dose response assessment. In 
11 
other words, to say how strong or weak a chemical may be in 
12 




So, our guidelines say pretty much what you just quoted 
15 
from the Office of Science and Technology policy. 
CHAIRMAN TORRES: Do you believe that the science policy 
16 
17 
repeated in your own Department of Health Services' guidelines 
J 8 
i should be used as a basis for setting public policy? 
i 
I] 
] 9 i! 
1: 


















DR. KELTER: It's an element of the basis of setting 
public policy, but public policy, going beyond science policy, 
includes the economic, political, and social considerations that 
our guidelines do not incorporate. 
Public policy, the making of decisions, the exercising 
of options for what to do about it, is based on a number of 
contributions, and our science policy in the guidelines should 






























CHAIRMAN TORRES: Then I'm confronting a word salad 
here, and I'm trying to figure out just where the greens, and the 
tomatoes, and on are. Let's see if we can get that into 
it specifically. 
DR. KELTER: Okay. 
CHAIRMAN TORRES: We have a policy in California now, as 
articulated by our own Department of Health Services, which says 
that it is not a public policy but a science policy. 
DR. KELTER: Science policy. 
CHAIRMAN TORRES: And as a result of that, since it is a 
,, science policy, we are not going to be asked the questions of 
what to do about it; we're just going to be asking the question 
of whether it is a carcinogen or not. 
DR. KELTER: Right. 
CHAIRMAN TORRES: But also we are thereafter asking the 
question or stating that the guidel s which the Reagan 
' Administration has put forward, the International Research Center 
for Cancer has put forward, and our own Department of Health 
Services has put forward in terms of guidelines, and that is that 
animal contact and experience ought to determine human risk 
factors 
DR. KELTER: Right. 
CHAIRMAN TORRES: are not going to be utilized in the 
determination of potential chemicals for this list? 
DR. KELTER: Well, I wasn't addressing myself to the 
Prop. 65 list. 
11 
My understanding is that the first minimum list for 
Prop. 65 was determined by the interpretation of the Act itself. 
And that subsequent revisions and consideratjons on additions or 
deletions from the list that are to be based on science will come 
from the recommendations of the Science Advisory Panel. 
My understanding is, the first list was based on the Act 
itself, not on Department's guidelines or !ARC's guidelines or 
anybody else's guidelines, but on the statute itself as passed. 
9 
CHAIRMAN TORRES: So you anticipate that the list may 
increase as a result of the Scientific Panel's review of all the 
10 
other chemicals which may or were not included within the initial 
list? 
DR. KELTER: I would anticipate that it may increase, 
yes. 
CHAIRMAN TORRES: And it may increase as a result of 
16 
following Department of Health Services' guidelines, or as a 
17 




DR. KELTER: No, my understanding is that the Panel will 
20 
be asked to consider the guidelines and will do so at its 
J! ,I 
21 lj 











25 I' I 
II 26 
II I, 
27 il ,, 
science-based criteria, that they will then add to or delete from 
the list based on those criteria. 
My understanding, and again you should hear this from 
the Agency rather than from me, but my understanding is that the 
Science Advisory Panel is strictly that -- science advisory. Not 










asked to do the same kinds of things that DHS' guidelines were 
asked to do: separate the carcinogens from the noncarcinogens. 
CHAIRMAN TORRES: So the Scientific Panel which the 
4 
Governor has appointed will incorporate as its standards the 
5 
Reagan Administration's Science and Technology Assessment, the 
6 
International Research on Cancer, and our own Department of 
7 




DR. KELTER: I don't know if they will or not. They 
10 
could, but whether they will or not, I would think, is going to 
11 
be up to them. 
12 
CHAIRMAN TORRES: From your own perspective, what would 
1 3 
prompt them not to adopt those well-grounded principles that seem 




I don't really want to speak for the Panel. 
Some of the elements included in our guidelines and the other 
16 
guidelines you referenced remain controversial in some scientific 
17 
circles. There are some scientists who don't believe that one 
18 
19 
can extrapolate from animal experiences to human. There are some 
scientists who don't believe that the models, for example, that 
20 
are used in DHS guidelines are applicable. There are some 
21 
scientists who believe that carcinogens have thresholds. There 
22 
are some scientists who believe that laboratory tests, such as 
23 




26 ll ,, 
:r 
experience. 
So in some scientific circles, there is controversy 
about these areas. The Department feels, from its own 
































perspective, that it has made choices in its guidelines that have 
some semblance of consensus in the general scientific community, 
but in other circles there are still controversies. 
So, I wouldn't try and speak for the Panel in deciding 
what they will do. 
CHAIRMAN TORRES: No, but you are the spokesperson for 
the Department. 
DR. KELTER: For the Department, and our guidelines 
speak fer themselves. We accept animal evidence for 
carcinogenicity in the Department's guidelines, and we use them 
to do risk assessments. 
CHAIRMAN TORRES: All right, and my question again is: 
Would you recommend then to the Scientific Panel that they ought 
to do the same? 
DR. KELTER: I think they would be wise to consider our 
guidelines carefully and those that are based on, including IARC 
and NTP. 
CHAIRMAN TORRES: Mr. Connelly. 
ASSEMBLYMAN CONNELLY: Thank you very much. This is 
very prestigious to let an Assembly Member sit with a Senate 
Committee. It only happens once in a while, so I'm allocated to 
three questions, so answer them carefully. 
(Laughter.) 
DR. KELTER: Okay. 
ASSEMBLYMAN CONNELLY: In light of the Department of 
Health Services' policy that animals are in fact good indicators 
for human carcinogens, IARC, NTP, EPA and so forth, did 
14 





Prop. 65, recommend to the Governor the full list of 250? 














ASSEMBLYMAN CONNELLY: Who they were. Was it you? Was 
II 
7 
:• it three or four different le? Who did it? 
8 
DR. KELTER: I actually don't recall. We did correspond 
9 
with the Interagency Committee early, after the Proposition was 
10 
passed. And I don't remember who signed the documents, but the 
11 
Department did make its recommendations. 
12 
ASSEMBLYMAN CONNELLY: Just so I'm clear on this point, 
13 
the Department of Health Serv s recommended to the Governor the 
full list of 250? 
14 
DR. KELTER: I bel what we said was: Were the list 
15 
I to be based on sc 
16 
if criter a , we would recommend the 
scientific 
17 
cr t are in the Department's own guidelines. 
18 
ASSEMBLYMAN CONNELLY: Senator Torres, is it appropriate 
19 
to ask that that correspondence be made available to this 
Committee and I think Members of the Tox s Committee on the 
20 
21 
Assembly side would like to see as well. 
CHAIRMAN TORRES: Yes. 
22 
23 
ASSEMBLYMAN CONNELLY: When I asked that, you understand 
24 
the request is all correspondence. It seems to me that it 
wou be help to see 1 recommendations to the 
25 
Department head, and then Department head's recommendations 
26 
to the task force so that we can understand how that 
27 
28 
recommendation was fact, it was made. 
15 
DR. KELTER: I'll certainly bring the request back to 
2 the Department. I can't imagine why, but if th~re are any 


























ASSEMBLYMAN CONNELLY: Thank you, sir. 
CHAIRMAN TORRES: Any other questions? 
Would you consider the selection of the individuals to 
the Scientific Panel by the Governor to represent the various 
schools of scientific thought? 
DR. KELTER: I'm not sure what you're asking. 
What I would say is, the Panel certainly represents a 
cross -- a full spectrum representation of the various fields of 
expertise that were called for for the Panel. 
If you're asking do the Panelists represent the parts of 
the scientific world that may have problems with the DHS 
guidelines, I'm not sure whether it really does or not. 
CHAIRMAN TORRES: You're familiar with the abilities and 
resumes of all of the members of the Scientific Panel. 
DR. KELTER: Most of them. 
CHAIRMAN TORRES: Would you consider all of them to be 
free of direct and indirect economic conflicts of interest? 
DR. KELTER: I'm not sure I'm qualified to answer that. 
I'm not personally familiar with a lot of the Panelists. I have 
seen sumrnaries of their curriculum vitae. 
My observation would be that the Panel represents a 
balanced view of the state of the science in the areas of 










4 II ,, 
CHAIRMAN TORRES: Were these individuals required to 
submit a Statement of Economic Interests? 
DR. KELTER: I don't know that. 





know if any attempts were made to determine the income of members 
!I 
6 II 









DR. KELTER: I don't know that. The Department of 
Health Services, at least from my jurisdiction, was not 
9 
responsible for doing that. 
10 i) 
CHAIRMAN TORRES: Who was, do you know? 
DR. KELTER: I would think it would have been done in 
11 
12 
the Health and Welfare Agency. 
13 
CHAIRMAN TORRES: The Health and Welfare Agency made 
those determinations? 
14 
DR. KELTER: The Health and Welfare Agency being the 
15 
lead agency did the lion's share of the work in assembling 
16 
recommendations for the Panel, yes. 
17 
18 
CHAIRMAN TORRES: I'm trying to get a focus on 
definitions. 
19 
DR. KELTER: Okay. 
20 
CHAIRMAN TORRES: The term "reproductive toxin", how 
21 
would you define that? 
22 
DR. KELTER: That's a good one, and I think it's going 
23 
to be one of the first very important tasks that the Science 
24 










As you know, Prop. 65 did not define the term 
































II li broad. Reproductive toxicity could include issues such as the 
I! malformation of a newborn in a species or human. It could 
include alterations in the fertility of the spec s, whether it's 
because of the effect on the male or on the female. It could 
include issues dealing with the size and state of health of 
offspring, whether it be a litter of animals or of humans. So, 
it could be a very broad term. 
On the other hand, it could be interpreted more 
~arrowly, depending upon the scientific context in which the 
definition was created. 
CHAIRMAN TORRES: Let's talk about that. 
Has your Department identified any reproductive toxins? 
DR. KELTER: We are still pulling in the responses from 
, our regulatory parts of the Department as to whether they have 
caused substances to be identified or labels as reproductive 
toxins. 
The three parts of the Department which might do that 
would be the San ary Engineering Branch, the Food and Drug 
Branch for the Toxics Division. Those are the three parts of DHS 
that have the regulatory authority to make such determinations. 
CHAIRMAN TORRES: Have you made a list of those? 
DR. KELTER: We're in the process of doing that. 
CHAIRMAN TORRES: And that's what this draft is about? 
DR. KELTER: I'm not sure what draft you have. 






























DR. KELTER: No. The Toxic Triage Priority Setting 
Document is intended for use of officials at the state or local 
level, or anyone else, trying to put uncharacterized hazardous 
waste sites in some priority order for characterization. 
Appended to that was a list of chemicals which have been put 
together and considered broadly reproductive toxicants. 
The data for those chemicals has not been assembled, 
reviewed, quality assured, or in any way adjudged by the 
Department. And I believe there's a disclaimer on the list which 
says that. 
We do not intend for that list to be judged as the 
Department's list of reproductive toxins. 
CHAIRMAN TORRES: So how did one qualify to get on the 
list? How did a chemical qualify to get on this? 
DR. KELTER: We had no criteria. We simply took the 
extensive lists of reproductive toxicants together by other 
scientists based on some or other kind of published data and 
said: Until a further review can be conducted, one may assume 
that these chemicals have at least some animal evidence for some 
kind of reproductive toxicity, but we have no idea whether the 
evidence is any good or not. For arbitrary purposes of ranking 
hazardous waste sites, if something's on this list, consider it a 
reproductive toxicant, but we're not putting forth the 
Department's stamp of science that this really is a reproductive 
toxicant. We're taking somebody else's word it. 
CHAIRMAN TORRES: Now ethylene dibromide, EDB, is 






























DR. KELTER: It is on our list and IARC's list of 
substances for which there is sufficient evidence in animals that 
it causes cancer. 
CHAIRMAN TORRES: Why wasn't that put on the Governor's 
list then? 
DR. KELTER: My understanding is that the first list 
produced under Prop. 65 was produced according to the dictates of 
the statute, not according to scientific principles. 
The Scientific Advisory Panel for Prop. 65 was not 
available to review the first list, and so the first list was 
intended to be one required by the Act, not scientifically 
generated, is my understanding. 
CHAIRMAN TORRES: So you at no time participated in 
helping or recommend, put together, the list that initially 
emanated from the Governor's Office? 
DR. KELTER: I was involved in some discussions about 
the list. And the Administration's issuance of that list is 
based on its desire and interpretation of the Act that the first 
minimum list is that required by the Act. 
CHAIRMAN TORRES: Would you consider that EDB is a 
potent mutagen? 
DR.. KELTER.: I believe there's plenty of evidence that 
EDB is a rather potent carcinogen and mutagen. 
CHAIRMAN TOR.RES: V'lhat does that mean in your opinion? 
DR. KELTER: It means that in experiments done on 
animals, a very high percentage of the animals administered EDB 












CHAIRMAN TORRES: So you would consider this a 
as well? 
DR KELTER 1 I' reproductive 
4 n 
data, but I 1 -- no, I 't bel I am not liar 
5 
with the reproduct data on EDB. 
6 
CHAIRMAN TORRES: If were an r and you were 
7 
familiar with the EPA's report on EDB, would you warn your 
8 
workers or potential employees to be careful around its use? 
9 
DR. KELTER: I would definitely, and my understanding is 
10 
that current federal and state law already requires such a 
11 
warning to be given. 
CHAIRMAN TORRES: Yet was not luded on the list to 
12 
13 
be kept out of our water. 
14 
DR. KELTER: My unders the first list was 
15 
constructed according to imum requirements of the Act. 
CHAIRMAN TORRES: min irements 
16 
: excluded a chemical 1 EDB? do you th that is? 
17 
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therefore, the first list was constructed according to our 
interpretation of the statute itself. 
CHAIRMAN TORRES: Wh is t? What is that 
21 
rpretation? That's what I'm having difficulty understanding. 
DR. KELTER: Not being an attorney, I don't think I 
could probably give the justification the t that it 
deserves from the legal point of view. I think it would be 
better to have someone more familiar with 
interpretation answer the question. 
at legal 
I would be able to interpret it, I think, if it were a 
scientific judgment, but my understanding is that it was not. 
CHAIRMAN TORRES: So a scientist looking at Proposition 
65 could not interpret what it meant because it could not 
interpret Proposition 65 from a scientific viewpoint? 
DR. KELTER: The first list, the min requirements 
for the first list, as I understand them, were hard to interpret. 
: And Counsel recomme and the Administration supported the 
interpretation of Act which resulted list that the 
Governor issued. 
As a sc ist, I honestly do not understand all of the 
intricacies of the legal interpretation that resulted in the 
first list. 
CHAIRMAN TORRES: But as a scientist today, you would 
have put EDB on this first list; wouldn't you? 
DR. KELTER: If the list were to constructed 
according to scientific gu 
for putting EDB on the list. 




CHAIRMAN TORRES: Mr. Connelly. 
I' ASSEMBLYMAN CONNELLY: ing to scientific 2 ,I ,, 
'I 
3 I! gu 1 s that 's to cause cancer. 
i' 
·' 
4 DR. KELTER: Ac to the Department's carcinogen 
5 
ii guidelines, wh inc and an l evidence that a 
6 substance may se risk of cancer, s. 
7 
ASSEMBLYMAN CONNELLY: This line of tioning is 
important because issue as to minimum only follows the 
9 
requirement that known carcinogen substances be listed. After 
10 
that it said at a minimum shall include, and then we get into 
this argument about the listing. 
12 
So the thing 's frustrating to me, and I don't want 
13 
to dump it on you because sounds like you made the 
14 
15 
Health Services d there's not a stion of a minimum. 
16 
The statute says known to cause cancer. And when you say based 
I 7 
upon the State's , IARC's , NTP and the Environmental 
18 
Protect i to cause cancer. It's one of the 
19 
250, and the of Heal Serv s recommended that it be 
20 
wasn't li , I get angry. Not at you, but I get listed, and 
21 
angry because that's not of the statute that 
talks about a m list. I S rt of the statute 
22 
23 
that says known to cause cancer. 
24 
And 're say is to cause cancer based 
on all State 1 
25 
26 
And I that's 1 of Senator's questions, 
27 






























frustration there, but it's not a legal issue. It's just -- it 
is a scientific determination issue with those three words. 
DR. KEL'l'ER: I understand your po t, and at the point 
when the scientific criteria determine the list of substances, 
those scientific criteria will come out of the Scientific 
Advisory Panel. 
Not to sound like a broken record, but my understanding 
is that the first list was constructed solely on grounds based on 
the wording of the statute, not upon scientific criteria. 
CHAIRMAN TORRES: Senator Rosenthal. 
SENATOR ROSENTHAL: I guess the frustration is, I guess 
they looked at it specifically from legalese, from the legal as 
they interpreted what the Initiative said. 
CHAIRMAN TORRES: Well, let's see hmv you would 
interpret it, Senator. 
SENATOR ROSENTHAL: Oh, I would have put 250 or 300 
items on there if fact var s departments had i icated 
that they were cancerous to animals, because I understand that if 
it's cancerous to animals, it's cancerous to humans. 
I mean, I haven't run across any of them that were 
cancerous to animals and weren't cancerous to humans. 
no problem. 
So, I have 
CHAIRMAN TORRES: Well, Proposition 65, just let me read 
it so we have a better idea of what we're dealing with. 
Proposition 65 states that a chemical is, quote: 
"known to the State to cause cancer or 
reproductive toxicity within the meaning 
24 
of this chapter if in the opinion of the 
2 State's experts it been clearly 
3 sc ifica val testing 
4 
according to generally accepted principles 
5 li 
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sort of a minimum list based upon known carcinogens that have 
il 
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been known to cause cancer in humans. And some of those that 
have been known to cause cancer in animals may not have been yet 




14 II 'I ,,
15 II 
between animals and s we are an animal of some form. 
CHAIRMAN TORRES: Is the issue before us, then, that 




could be made? Is that we're faced with? 
17 
I you're not a I'm just asking. Is 
18 
that what you've around the Department? 
19 ll 
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22 i' !I I! 
Phrases in 
defined in the Propos "General accepted scientific 
principles" in some cases are of the beholder. We 
'I I 23 ,! " 'I 
will ask the Scientif isory Panel what they think "generally 
li 
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'I 
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26 II d 
II 
I! 
accepted scientific s" are. 
CHAIRMAN TORRES: quest s of this witness? 
Thank you. 





















CHAIRMAN TORRES: Give our best to Dr. Kizer. 
DR. KELTER: I will. 
CHAIRMAN TORRES: Is Mr. Secretary Allenby here, 
Clifford Allenby? 
MR. WARRINER: No, he isn't. I'm Torn vJarriner. Mr. 
Allenby was unable to be here this morning. 
CHAIRMAN TORRES: How do we know you're really Mr. 
Warriner? 
(Laughter.) 
MR. WARRINER: Well, I have my Driver's License. 
CHAIRMAN TORRES: Under the new immigration law, that 
would not be sufficient. 
(Laughter.) 
MR. WARRINER: Actually, when I'm not doing Prop. 65, 
I'm trying to ensure that the State gets a good share of the 
money under the Immigration Reform Act, too. And actual a 
7.5 














CHAIRMAN TORRES: One. 
MR. WARRINER: Yes, there's six others, of which none of 
us have with us. 
CHAIRMAN TORRES: That's correct. 
MR. WARRINER: But I have my driving license. 
CHAIRMAN TORRES: Well, welcome to the Committee, Mr. 
Under- Secretary. I know you've been under a lot of pressure. 





























CHAIRMAN TORRES: Have you really? Probably from 
drinking some of the water that you should have included some of 
the chemicals 
(Laughter.) 
MR. WARRINER: No, no. According to my wife, I'm 
probably not drinking enough water and drinking other things. 
CHAIRMAN TORRES: Well nevertheless, welcome to the 
Committee. 
MR. WARRINER: I'm pleased to be here. 
ASSEMBLYMAN CONNELLY: Senator, I'm going to go over to 
the Assembly. I just got a note they've started to pray over 
there, and so I try to get there right when the prayer's going to 
start. 
So thank you for letting me sit in. 
CHAIRMAN TORRES: That's right, you are marrying a 
minister; aren't you? 
ASSEMBLYMAN CONNELLY: That's correct. 
. ) 
MR. WARRINER: Shall I begin? 
CHAIRMAN TORRES: Please. 
MR. WARRINER: were a lot of questions that I'm 
sure will find their way to me after we get started, but I 
thought I might do a quick overview in terms of what we've done 
to this point on Prop. 65 implementation. 
Then, if ses Chair, I 11 go through the 
questions that were asked the tter, and then of course, any 
other questions that might still be unanswered. 
27 
CHAIRMAN TORRES: The Members, I think, have a letter in 
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We're also beginning to confront the issue of warnings. 
One of the most, I think, significant parts of Proposition 65 is 
the provision for warnings ich to g to people who 
are exposed to chemicals listed. 
We've put together a group of people that includes 
government specialists, consumer specialists, and producers and 
the sellers of products in hopes of coming up with some good 
ideas that will give the consumer a good warning and also not 
burden more than is necessary to provide that warning the 
delivery system for goods and services in California. 
If the Chair pleases, I could start to answer the 
questions. 
CHAIRMAN TORRES: Please. 
Mr. Olsen, would you please come forward. We didn't 
mean to exclude the minority consultant to the Budget Committee. 
MR. WARRINER: This is on the letter dated March 11, 
1987 to Secretary Allenby; Sa Dr ing Water and Toxic 
Enforcement Act Sc ific Advi Panel: 
"What selection criteria were used in 
selecting members of the Scientific 
Advisory Panel?" 
What we did, as you know, the Governor by Executive 
Order established a cabinet level working group, and involved 
Health Services and other department and agencies effected by 
Proposition 65. 
We reviewed the Proposition and determined those areas, 
those disciplines that were important to have on the Panel for 


























When we identified the six disciplines that seemed to be 
relevant, we determined that we should have at least two of each. 
In some areas, t toxici was particularly 
important because there are male and female specialists from 
within the different discipl s. 
We then had each of the departments or agencies named in 
the cabinet level working group nominate people for inclusion on 
the Scientific Advisory Panel: two for each discipline, plus two 
alternates. Those then were reviewed by all the other 
participants in the work group and ranked. And it's from that 
list that the Governor selected the Panel that now is acting or 
will soon be acting on the 31st. 
"Were appointees required to 
current or past sources of d 
rt on 
t or 
tion by irect income 
Governor of 
What we d was, we 
scribed how Panel was go 
protocol requires a 1 disc 
to se 
members?" 
r a protocol that 
to operate. And a part of that 
of all outs income. Since 
many of these people were academics, we also required disclosure 
of sources of funding that would go to the un rsity and might 
in some way be to the benefit. 
Now, I personally talked with each of the twelve people 
who were selected by the Panel, ten in person and two on the 
telephone, and prov them i wr ten material dealing with 




the need for a full disclosure of all their assets and dealt also 
30 














and that that statement to available at or before 
the first meeting of the Panel. 
All of them agreed, of course, to do that. All of them 
6 
under questioning felt there would be no conflict situation. 
7 
They've all been provided with the Conflict statement, the same 
8 
one that all of us fill out, which has been adjusted since it has 
9 
the academic components if the money goes to the university, and 
10 
then they don't necessarily get salary because of it, but it 
11 
could effect their success in the academic community if they were 
12 
people who brought in a lot of research money that would be to 
their benefit. So we wanted to identify that. 
13 
The statements are not in yet, but they will be in, and 
14 
they will be made publ as soon as we have them. 
15 
"Will the panel app a standard for 
16 
the definit of ' carcinogens 
17 











by the Governor in establishing the list 
of 'chemicals known to cause cancer or 
reproductive toxicity'?" 
" li 
22 II [I 
23 il ll 
My belief is that they will. 
"What legal authority will the advisory 
il 









committee operate under?" 
They operate under the author granted them by the 
Proposition itself which talks about a panel of scientific 
experts and seems to provide sufficient authority for that body 




























"How does the Administration plan to 
fund the activities of the Advisory 
Panel? If a budget change proposal will 
be made, what is the anticipated date 
of that request?" 
31 
They will be funded and a budget change proposal will be 
made, and it should be here in the next several weeks. That'll 
be in the form of a finance letter which will take into 
consideration not only the support for the Science Advisory Panel 
but the other staff that'll be necessary to implement Proposition 
65. 
Item Number Two: 
"Governor's List of Chemicals Known to 
Cause Cancer or Reproductive Toxicity. 
"What scientific standard did the 
Agency or the Governor apply when issuing 
the list of 29 carcinogens and repro-
ductive toxicants." 
That is the issue on which there are already some 
questions. Again, for purposes of the initial list, it was 
treated as a legal question to be determined based upon the 
Initiative itself, the language that talks about at a minimum, 
and also by reference to the arguments contained in the ballot 
proposition and the information contained in the IARC and NTP 
lists. 
That exercise for the initial or primary list was 
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Published in the Notice Registry and will be a part of 
Title 26 of the California Administrative Code is the safety 
determination process. 
Basically it was the feeling that a danger posed by 
Proposition 65 was if people became anxious and concerned, that 
they had questions that they needed to have answers to, and if 
there wasn't a good way to answer those questions, that people 
would make decisions not based on what the law requires but based 
on some emotional reaction or fear anxiety. The campaign 
surrounding Proposition 65 was one that attracted a great deal of 
attention, and I think there were things possibly said in that 
campaign which might frighten people and force them to make 
decisions regarding plant location and whatnot which are not 
warranted under Prop. 65. 
So the safe use determination process was intended to be 
,, a way to avoid any pernicious effect the Proposition would have 
by uncertainty and confusion in that it creates a process by 
which questions can be asked by people effected by the 
Proposition and by which they can receive, hopefully, prompt and 
helpful answers. It does have a PY implication and is part of 
the BCP put together to answer those needs because there will be 
staff requirements connected with the safe use determination 
process. 
"What will be the standard upon which 
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MR. WARRINER: But 'm ing very quickly, PYs are 
9 
personnel years, s. 
10 
I thought "peop 11 be , but --
11 
CHAIRMAN TORRES I saw some of the correspondence in 
absolute di d 
12 
not "PY" was. I just 
wanted to sure 're aware of 
13 
MR. WARRINER: I'm plea that there are still some 
14 
fe says I've lost 
15 
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The standard will basically -- if the SUD asks a 
question as to whether a particular use of the chemical is within 
or without 65 -- that is, is it a significant level of the 
chemical or not -- that's a scientific question and we would 
apply basic scientific principles by whatever operating agency 
had the most relevant experience in the area. 
There's not a standard of evidence such as you might 
have in a civil trial. 
CHAIRMAN TORRES: Are you familiar, Tom, with the 
standards that I articulated earlier to Dr. Kelter? 
MR. WARRINER: Yes, sir. 
CHAIRMAN TORRES: Are those the standards, those three 
types of standards? Will that be the standards that'll be used 
by the Scientific Panel? 
MR. WARRINER: I should correct something that your 
question suggests maybe in your mind. 
The SUD process does not involve the Scientific Advisory 
Panel. The SUD process involves a regulatory agency. 
CHAIRMAN TORRES: Which is you. 
MR. WARRINER: Which is the Health and Welfare Agency as 
the lead agency, and all the departments -- the Water Board if 
the SUD had to do with discharges into water; the Health 
Department if it had to do with areas of their traditional 
control. 
So, that is a separate process, and the Panel itself 
would be concerned with adopting either the EPA standards, the 
Health Services standard, the IARC standard, the NTP standard, or 
some synthesis of all of those. 
36 
We're o those to the Panel 
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"What effect will SUDs or interpretive 
2 guidelines have on regulatory action by 
3 
departments or agencies other than the 
4 
Health and Welfare Agency?" 
5 
I answered that question. 
6 
"Given the potential complexity of 
7 
determining whether a significant 
8 
risk is present for each request of 
9 H 
a SUD, will a $500 fee allow the Agency 
II 













The answer to that is two-fold. One, it's a $500 filing 
fee plus any cost in excess of $500 to the State incurred in 
responding to the SUD. There's also provision in the procedures 
to waive the fee. 





My concern was that people like Chevron Oil Company 
16 
don't really need the State. Chevron has lots of scientists and 
toxicologists who can make their individual decisions, and 
17 

















Chevron can decide what to do. 
I'm not picking on Chevron. I'm using them as an 
example. 
But there may be lots of people who employ 13 employees 
who have a question about the Proposition, and there needs to be 
a way to respond to them. And if their response requires a great 
•I 
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needs of small business people as well, since in a sense the SUD 
process might help to even up the playing field in terms of 
















4 'I !I 
MR WARRINER If there s a numeric 
ij 
5 II II 
standard ava f the 
6 'I II 




i wou lati to 
8 
lar use of 
9 
In some instances some als, the SUD be the 
lO 
first t that ssue of use of al might be 
con 
11 




di al di are not now available. 
14 
15 
ant SUD process 
t l st 
I 39 
I 
1 IJ thing. We need to have at least a consistent standard when it 
II 'I comes to particular chemicals, and we hope the SUD process would 2 li 
I' 
3 ~~ allow for that development. 
4 
CHAIRMAN TORRES: Did I hear you correctly earlier to 
5 
say that the SUDs could be used as a defense in terms of a 
6 
discharge against penalties contained in Proposition 65? 
7 
MR. WARRINER: It would seem to me that if a company had 
8 
applied and received a SUD that determined that their particular 
9 
use of a listed chemical was not a significant, was not 
significant for purposes for Prop. 65, then that would be a piece 
10 " 
of evidence which could be offered. 
II 
12 
Likewise, if the application for a SUD turned out that 
13 
the use was in Prop. 65, was a significant, then that would be 
14 
evidence which a district attorney could use. 
15 
We're neutral. I mean, we issue them like an Attorney 
16 
General's opinion, based upon our judgement, scientific judgement 
as to what the correct answer is. 
17 
I 8 
CHAIRMAN TORRES: But you're in communication with the 
19 




MR. WARRINER: They are aware of the SUD process. I 
22 
have not heard anything from them contrary on that. 
23 
CHAIRMAN TORRES: I see. Do you plan to communicate 
24 
with them in terms of procedural guidelines from their 
25 
perspective? 
MR. WARRINER: I would expect that we will hear from the 
26 
27 
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SENATOR GREENE: So t instanc I ' firms 
be rating as do now? 
MR. WARRINER: Oh, yes. They're not 1 ted. 
go ahead and take your chance. We're only trying to offer 
services to people who might want to use them. 
would 
You can 
CHAIRMAN TORRES: Yes, I understand that, but that 





















and that is that if a specific company requested or did not seek 
" to request a SUD, 
without any review 
could go on discharging certain elements 
the Agency. 
MR. WARRINER: No, that's not true. 
A SUD is a way for people to know in advance what the 
science of the particular use would be; what would be the 
outcome. 
CHAIRMAN TORRES: Right. If their scientific experts do 
, not want you to know what the scientific outcome is, how then 
would you proceed to do so? 
MR. WARRINER: You would be -- they would be involved in 
the existing regulatory function. If they were discharging into 
the drinking water system, monitoring currently goes on. The 
monitoring would continue to go on as to chemicals listed in 
Prop. 65, so the Water Boards would be monitoring and would know 
if the people were improperly discharging. 
CHAIRMAN TORRES: Is it your interpretation, then, that 
if that discharging is occurring, and if a company does not 
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CHAIRMAN TORRES: I understand that, but if the company 
doesn't request a SUD, then there is no record of a public notice 
because no request has been made. 
MR. WARRINER: That's right, and that industry would be 
at its own peril if the discharger failed to warn. 
CHAIRMAN TORRES: Well, they may decide that their 
discharge is much more important to them than the peril of the 
penalty under Proposition 65. 
MR. WARRINER: That's a risk that exists. 
!0 " 



















,, discharges in other parts where certain companies feel that a 
$5,000 fine is worth the risk rather than dealing with the whole 
other issue of cleaning it up. 
MR. WARRINER: What we had tried to do through the SUD 
process is not -- we can't grant exemptions under 65. 
Proposition 65 exists and is binding on everyone who uses 
chemicals that are listed. That's nothing we do. 
All we d was try to make available to people who might 
be effected by the use of the chemical an opportunity to find out 
what the State's view of the science is. 
So, we're neutral. I mean, it doesn't matter who asks; 
we issue what we believe to be the correct answer under the facts 
of that particular chemical. 
CHAIRMAN TORRES: I understand your neutrality in terms 
of the procedural aspects of this Act, but you are not neutral 
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just give them a short, you know, quickie job. They don't do a 
2 good job. 
3 They give it to the firm. The firm paid them under a 
4 contractural basis in good conscience and what have you, and the 




not check their data enough. I can very well see that happening. 
The people are not doing it intentionally or anything. 
But then they get caught in the process. And everybody 
9 that does it maybe aren't necessarily doing it intentionally. 



















in-house technical expertise, they go outside to get it. 
You know, it's a brand-new field. Very few people 
really know it. And it's very easy to give people a half job, 
three-quarters of a job. 
MR. WARRINER: Senator, that was one of our concerns 
about the SUD process. 
We do have scientists that do decent work. I mean, the 
Health Department, as you learned earlier today, is I think on 
the leading edge in a lot of these areas. So we want to make 
good use of those people. 
We don't want people to make silly decisions based upon 
a misapprehension of the facts. And there is some anxiety that 
this is a new area, and that maybe there isn't out there all the 
resources, private resources, that the State would provide a 
useful service in doing this. 
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MR. WARRINER: Yes. 
"Upon what basis did the Health and 
Welfare Agency make the determination 
to define employees to include both 
full and part time employees?" 
47 
I think I'm responsible for having made that decision. 
r: And it may not make me particularly popular with some people who 
have a lot of part-timers, but our feeling was there is no time 
reference in the Initiative itself. So, we figured that what was 
intended was that we look at the day when the discharge took 
place, and if you've got the right number of employees on that 
day, then that's the number of employees that you have for 
purposes of that application. 
Otherwise, if you average the number of employees over a 
year or two years, you can't draw that language out of the 
Initiative. So we picked an interpretation that says count noses 
on the day you have the discharge, and if you come up with the 
right number, you're within the provisions of Prop. 65, even 
though other days during the year you might not be. 
We felt that that was concerned with exposure to people, 
and if you were exposing that number of people on that day, then 
you should be effected by the Proposition. 
"Please clarify your Agency's 
interpretation of the definition 
of 'knowingly'." 
There is an Attorney General's opinion, a preliminary 
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If you look at the typical mid-range on the cancer side 
would be one additional cancer based upon a million exposures, 
but I think we'd like to ask the Scientific Advisory Panel's 
recommendation on that. The midline is what Health Services has 
typically been using. 
"In addition to your testimony, the 
Committees would appreciate receiving 
the following documents and material." 
I've already provided copies of the correspondence from 
the Agency and the Health Department regarding the Panel. 
The financial disclosure forms, they'll be submitted as 
soon as we receive them. It should be within the next two weeks. 
And so far, no one's asked for an interpretation or a 
SUD, but I think business will pick up. I have every reason to 
believe it will pick up. 
CHAIRMAN TORRES: Did the Department of Health Services 
make any recommendations to the initial list? 
MR. WARRINER: Yes, they did. 
CHAIRMAN TORRES: Were those recommendations accepted or 
rejected? 
MR. WARRINER: They were both. 
CHAIRMAN TORRES: Which ones were rejected? 
MR. WARRINER: They recommended -- I think you could 
call it a recommendation -- that on strict scientific grounds, 
the initial list should be the initial list we published, plus 
the candidate list. 
50 
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identifying the candidate list in the same way that we identified 
the initials. Both lists are published. 
CHAIRMAN TORRES: When you say "known" and "suspect" --
MR. WARRINER: Correct. 
CHAIRMAN TORRES: -- where do you place EDB? As a 
suspect chemical then? 
MR. WARRINER: For these purposes, it would be a suspect 
chemical. 
CHAIRMAN TORRES: Even though it is known to cause 
cancer. 
MR. WARRINER: One of the difficulties is, when you look 
at the IARC and NTP lists, they use "known" as chemicals for 
which there is human study information. The "suspect" chemicals 
for them are chemicals where there is limited human information 
but animal cancers. So the interpretation we used for the 
initial list, the primary list, is based upon the IARC and NTP 
and the references contained in the Initiative to have the first 
list contain only those that are, quote, "known", and the second, 
the candidate list, is the list which the Panel is charged with 
immediately reviewing, and the Panel's obligated to review it 
within a year and will be making quarterly updates to move 
chemicals off of the candidate onto the primary list as the Panel 
reviews them. 
CHAIRMAN TORRES: But the International Agency for 
Research on Cancer, which is the one you quoted --
MR. WARRINER: Right, IARC. 
CHAIRMAN TORRES: Right, says that: 
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CHAIRMAN TORRES: Who was counsel who advised you 
2 
throughout this initial process? 
3 
MR. WARRINER: We received legal advise from the 
4 
Department of Health Services. 
5 




MR. WARRINER: Robert Tousignant. I can supply a copy 
8 
of the legal opinion. 
9 
CHAIRMAN TORRES: We would like to see a copy. 
10 
MR. WARRINER: Surely. 
1 I 
CHAIRMAN TORRES: Any further questions? Senator 
12 
Seymour, Senator Greene. 
13 
SENATOR SEYMOUR: As I listen to the discussion taking 
14 
place and asking the question of: Is the initial list 
15 
sufficient: does it comply with Proposition 65; was the intent 
16 ' 
for lengthening that list? 
I want to make sure that what I'm hearing is in the 
17 
18 
Department's opinion accurate. What I am hearing is that it is 
19 
the Department's opinion that at this particular stage, the 
20 
Department and the Administration in publishing their list has 
kept with the total intent of the law of Proposition 65. 
21 
Is that true or false? 
22 
MR. WARRINER: Yes, Senator. 
23 
SENATOR SEYMOUR: And further, that we can expect, as 
24 
the Scientific Panel progresses with its studies, that that list 
25 





MR. WARRINER: I rea to bel 's 
It 
2 ;} lr 




i trat sture that 
ii 
5 !! II 








SEYMOUR: 250 on list, 
9 
were wrong, and s 
10 
240 or 120 or 8 , 'd back off. 
ff ion 
2 
mean wou ls on 









II SENATOR SEYMOUR: My last question, Mr. Chairman. 
II 
2 Are there any known carcinogens that have been left off 
3 the initial list of those known and published by these agencies 
4 and scientific bodies you've been describing? 
5 
MR. WARRINER: The Governor's initial list includes 
6 , every known human carcinogen identified by the World Health 





SENATOR SEYMOUR: Thank you. 
10 




SENATOR GREENE: I have two questions. One is a 
13 
follow-up on the question that Senator Seymour was asking. 
14 
You say that there are some substances which are not on 
15 
all the lists. Are there any which are only, say, two of the 
lists and not on the third? 
16 
17 
MR. WARRINER: I can't answer that question. 
18 
SENATOR GREENE: Because I was going to say, if you had 
that situation --
19 
MR. WARRINER: Two out of three. 
20 
21 
SENATOR GREENE: -- it seems that in terms bf complying 
22 
with the law for the safety of human beings, that that would 
23 
maybe be grounds, even though they might not be on the third 
list. You can't answer that. 
24 
25 
You made reference in your testimony that you are 
26 
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MR. WARRINER: It is very important to me. And it's 
important to me that we get it to the Legislature soon enough so 
that there can be meaningful debate and review over --
SENATOR GREENE: Because you're going to be criticized 
if you don't, and it's going to make you look bad. You know, 
it's going to make you look like you're dodging. 
I'm not accusing or anything; I'm just stating a fact. 
It's going to make you look bad; it's going to look like you're 
dodging. And if there's criticism now, this is just going to be 



















MR. WARRINER: And I do not want to add to that. 
SENATOR GREENE: Well, that would do that. You can see 
that that would do that; right? 
MR. WARRINER: Yes, sir. 
SENATOR GREENE: And particularly with my mentioning it 
now. 
(Laughter.) 
MR. WARRINER: Yes, sir. I have the very distinct 
impression you have a strong feeling about this. 
SENATOR GREENE: Well, it's just in terms of being able 
to do our work. You know, I assure you, I'm not expert in this 
area. But we can fumble our way through if we have enough time 
to do it. 
MR. WARRINER: I would only think it would be valuable 
to us to get a full legislative review of the proposals because 
this is a new area we're working on. This is not something where 
you can draw on necessary history to tell you what the correct 
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Why didn't somebody give some thought to doing thot type 
of thing? Instead of 250 or whatever the number everybody thinks 
there is, but the 75 that everybody says is? 
MR. WARRINER: I think -- what we did was, we put 
together the Scientific Advisory Panel; we put together the Panel 
with a charge to go through the chemicals, the entire suspect 
list, within twelve months. We've committed to a --
SENATOR ROSENTHAL: I'm not talking about within twelve 
months. I'm saying that had you done something, just somebody 
who is not a scientist, taken all the lists, and I'm not a 
scientist, it would have been simple for me to say: Hey, what 
does everybody consider to be a carcinogen. 
MR. WARRINER: Right. 
SENATOR ROSENTHAL: EDB, whatever. Was that left off of 
anybody's list? 
MR. WARRINER: I understand what the Senator's saying. 
Our feeling was that it was best to have the Panel up 
and operating, and have the Panel do that. We're going to do it 
every three months, we're going to update that list until we've 
gone through the entire candidate list. So, we may be further 
along on this road fairly soon. 
CHAIRMAN TORRES: It's 90-day updates? 
MR. WARRINER: That's our plan, at least in the first 
year. After the candidate list has been gone through, we're 
obligating the Panel to keep meeting at least twice a year. But 
the candidate list represents the initial commitment. After 
that, IARC and NTP produce chemicals on a regular basis that 
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CHAIRMAN TORRES: We're go to reconvene the Joint 
9 
Committee. Our star assistant is back now and ready for action. 
lO 
I'd like to welcome to the Committee Dr. Steve Book who 
11 
is Execut Sec the Sc if Advisory Panel on 
12 
Proposition 65, Safe Dr Water In iat 
13 
We to the , Doctor. 
14 
DR. BOOK: Senator. 
15 
I real 't comments. 
16 
CHAIRMAN TORRES: do 
17 
, small I recent newspaper 
18 
you s was f lly 
19 
You that ld been other chemicals 
20 
ed on s 
I 
21 
DR. of Health 
22 
23 
Services, or I I still am the Department ss 
24 
of Health to Deputy Director I 
that I istent w the 
25 
26 
Departmental 1 we discussed, 




1 carcinogenicity in animals should be included on the initial list 
2 for Proposition 65, because as has been stated before, we do 


























CHAIRMAN TORRES: As Executive Secretary to this new 
Scientific Panel, what are going to be your guidelines in 
determining inclusion or exclusion of chemicals within the list? 
DR. BOOK: My function as Executive Secretary to the 
Panel is to really serve the Panel. The direction for the Panel 
will be dictated its Chairman, Dr. Kilgore, and by the Panel 
itself. 
So, I'm primarily there to assist them in making their 
decision. 
CHAIRMAN TORRES: I understand that, Dr. Book, but you 
and I both know that staff people, where ever they may exist or 
be, have recommendations. They are not there as mutants merely 
to serve the will of a particular committee or panel or 
: organization. 
You have your thoughts, and I'm sure you're going to 
prepare a briefing book; are you not? 
DR. BOOK: Yes, Senator. 
CHAIRMAN TORRES: And part of that briefing book, I'm 
sure, will be to outline the various parameters of the issues 
regarding Propos ion 65. Isn't that the case? 
DR. BOOK: Certain 
CHAIRMAN TORRES: And one of those parameters is going 
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DR. BOOK: Yes, sir. 
CHAIRMAN TORRES: And in this book, the guidelines 
state: 
II most substances 
one an l 
found to care 
species when adequa 
Is that a correct statement? 
t are carcino-
s are also 
r animal 
tested." 
DR. BOOK: Probably so, sir. I can't recall exactly. 
CHAIRMAN TORRES: All right. And: 
DR. BOOK: Yes. 
CHAIRMAN TORRES: And 
recommendation? 
DR. BOOK: It'll be 
ided to Panel. 
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experimental b ists there is an apprec ion for the 
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universality of mammal stems, 11 take that 
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into account. is, if a is carcinogenic in several 
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animal species, then is likely that it is carcinogenic in 
8 
other species. And I'm sure that they will take that into 
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account. 





CHAIRMAN TORRES: How many chemicals are on the present 










DR. BOOK: 's 26 care and 3 reproductive 
CHAIRMAN TORRES: That's 26 carcinogens and 3 
t tox s? 
15 
DR. BOOK: Yes. 
16 
17 
CHAIRMAN TORRES: Do that EDB may be one ant 
:' of se t 1 on the list? 
DR. BOOK: not as a reproductive toxin, but as a 
carcinogen. 
CHAIRMAN TORRES: As a carcinogen. 
ls d Department of Health 
Services recommend inc within the first list which were 
exc ? 
DR. BOOK: 1 -- memo I wrote to the 
Director's f ls signated by IARC and 
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s. 
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CHAIRMAN TORRES: And that's a standard which Mr. 
2 
Warriner ind a to us earl r, the World Health standard? 
DR. BOOK: Ye . 
3 
4 
CHAIRMAN TORRES: Is possible to obtain a copy of 
that memorandum? 
5 
MR. WARRINER: I th that's what also asked Dr. 
6 
Kelter. He has a copy of , I'm sure. But we'll be sure that 
7 
you get that as well. 
8 
CHAIRMAN TORRES: It would be very important to us to 
9 
10 
determine just how the decision making process actually takes 
, place in the Department and the Agency. Help us in making a 
1 1 
better judgement call. 
12 
Any questions? Senator Greene. 
13 
SENATOR GREENE: I have one question out of curiosity. 
14 
Do you have any knowledge as to your suggestions 
15 
, were not llowed th ? Were given any information, 
16 
or did you inquire, or was any offered as to why your initial 
17 
recommendat s were not 1 on? 
18 
DR. BOOK: Well, I th lf of my recommendations 
19 
were. I was 
20 
SENATOR GREENE: Well, I meant the entirety. 
21 
DR. BOOK: W to the 1 formation and the 
22 
publ right to know about the chemicals that are carcinogenic in 
23 
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determined on a 
criteria. 
1 cr r than on scientific 
SENATOR s l cr ? 
DR. BOOK: Mr. Warr can discuss that better than I 
can. I'm not a r. 
SENATOR GREENE: was re to you; was it 
not? 
DR. BOOK: I bel to do some -- some 
difficulties interpreting in interpreting the Proposition from 
a legal perspective. 
CHAIRMAN TORRES: Is your counsel here? 
clear 
MR. WARRINER: Mr. Tous 
CHAIRMAN TORRES: Yes 










CHAIRMAN TORRES you p se i yourself. 
MR. TOUSIGNANT: Sure 
I'm an Assistant 
Services. 
f Counsel 
name is Tousignant, and 
of Health 
CHAIRMAN TORRES: Welcome to the Committee. 
Senator Greene, would you 1 to ask question 
again. 
SENATOR GREENE: was legal question that 










Californian seemed to interpret it pretty clearly. What was the 
difficulty you had? 
MR. TOUSIGNANT: I th , as Under-Secretary Warriner 
identified earl r, I mean, the basic legal question relates to 
whether or not the references to the Labor Code sections that are 
included in the minimum list requirement of the Proposition are 
clear on their face, or whether there is some latent ambiguity in 
those references. 
SENATOR GREENE: What does that mean? Explain that 



















what is it that is unclear? 
I understand what you said, but you haven't been 
specific. Would you please be specific. 
MR. TOUSIGNANT: The Proposition re rs to Labor Code 
Section 6382 (b) (1) and 6382 (d). 
SENATOR GREENE: All right. 
MR. TOUSIGNANT: Those are two sections which relate to 
a list of chemicals that is published by the Department of 
Industrial Relations. 
SENATOR GREENE: All right. 
MR. TOUSIGNANT: The second of those --
SENATOR GREENE: Which relates to workers on job sites 
and employers. 
MR. TOUSIGNANT: That's right. The second of those 
references includes -- aga refers to federal regulations which 
relate to occupational health and safety, and those regulations, 
it's the federal Hazard Communications Standard, require 
68 
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MR. TOUSIGNANT: To a degree, but again, it was -- I 
think it's the implementation process to ask the scientists to 
review what is known about the carcinogens which are listed by 
international organizations as potential carcinogens or suspect 
carcinogens to identify which of those in their view are known to 
the State to cause cancer. 
SENATOR GREENE: On that point, what are these 
scientists going to do to go out and prove one way or the other? 
: Are they going to do out and conduct some experiments on people 
9 
10 
or what? Because they're going to draw on the body of knowledge, 
1 l 
the body of research, the 
12 
CHAIRMAN TORRES: Just so they don't do it on my body. 
13 




SENATOR GREENE: So, they're going to review all the 
16 
data and all the research and what have you, and if no one has 
17 
conducted any additional research since the last research, what 
18 




MR. TOUSIGNANT: Presumably they'll decide based on the 
21 




SENATOR GREENE: Yes, but that data exists now though, 
24 
sir, that's my point. 
MR. TOUSIGNANT: That's correct. 
25 
26 
SENATOR GREENE: So if they can do it later, why can't 
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Again, the dist tion is for purposes of the initial 
list, not for -- the distinction is not for purposes of what the 
Scientific Advisory Panel will do starting the 31st of this 
month. 
CHAIRMAN TORRES: We understand that, but it's still 
very unclear as to why ambiguities which Counsel raised here had 
an impact as they did on known carcinogens, like EDB, which we 



















carcinogen, yet that carcinogen was not included within the list. 
MR. WARRINER: The Proposition 
CHAIRMAN TORRES: And the rationale is, the reason it 
was not is because there was some legal problem. Now we hear the 
legal ambiguities, and those legal ambigu s really do not seem 
to have relevance to the issue of known carcinogens. 
MR. WARRINER: They do. 
The sit arguments s "known" not "suspected". 
That's the terms that are used at least two times in the ballot 
arguments. 
CHAIRMAN TORRES: Are you suggesting to this Committee 
that EDB is not a known carcinogen, it's merely suspected? 
MR. WARRINER: The question is not what the Scientific 
Advisory Panel. 
to do under the 
The question is what the Governor was required 
it for the in ial list. 
CHAIRMAN TORRES: I understand that, Mr. Warriner, and 
that required some mens re, some understanding of what was going 
on. 
72 
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CHAIRMAN TORRES: Good heavens! It would just assume 
common sense that that would have been the case because of the 
evidence that we have on most of carcinogens. 
Excuse me if I'm incorrect, but most of the evidence we 
i have on most of the carcinogens that are well, quote, "known" to 
the scientific community to be mutagens, to be reproductive 
toxins, to be carcinogens, are based upon animal tests; are they 
not? 
DR. BOOK: That's correct. 
CHAIRMAN TORRES: And as a result of those animal tests, 
we have certain restrictions on their usage, if not restricted 
period. Isn't that correct, based upon those animal tests? 
So I don't know who -- I'm trying to figure out who is 
" talking to whom in this whole experience. It just boggles my 
mind as to trying to figure out how could an initiative even be 
more closely or better written in the future, because that's the 
i other thing in the back on my mind as we begin initiatives and 
the process. 
How do we write them more carefully so we don't have 
this burro-cratic interaction which results in confusion? 
SENATOR GREENE: Mr. Chairman, on your point, which goes 
to the same thing. 
The voters do not vote on the argument. They vote on 
the Initiative. You keep referring to the argument. 
The argument is not a part of the question. The 
question is on the Initiative. 
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So terms f 't implement 
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of construing the 
Initiative --
10 
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You will not communicate with the Attorney General as to 
his interpretation or her interpretation at some future date on 






MR. WARRINER: We did in this case, yes. I can't speak 
6 
for what future initiatives might bring to us. 
7 
CHAIRMAN TORRES: I understand that, and I'm not asking 
8 
you to speculate. I'm just asking, given this particular 
9 
instance, you relied on in-house counsel and no communication was 
10 
made to the Attorney General for an Attorney General's opinion? 
I l 
MR. WARRINER: We did not request an opinion on this 
12 
subject. 
CHAIRMAN TORRES: Pardon me? 
13 
14 




CHAIRMAN TORRES: On a subject of this magnitude, no 
request was made for an Attorney General's opinion to make sure 
17 
18 
that you covered 
19 
MR. WARRINER: Well, there are undoubtedly lots of areas 
20 
in which Attorney General opinions are not requested. I spent a 
lot of time in the Attorney General's office. We got a lot of 
21 
22 
opinion requests, but not every possible subject is explored by 
way of an opinion. 
23 
CHAIRMAN TORRES: I understand that, Tom, but this is 
24 
not an Initiative to deal with, you know, signposts. It's an 
25 
initiative which was probably one of the most controversial 
26 
initiatives on the ballot in 1986. It was not an initiative that 
76 
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I not, I re on islative 
8 
Counsel to gu the act of this if it involved a 
9 
substantial controvers 1 issue. Nor would I think any other 
10 
Member of is islature would. They would request the 
11 
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ASSEMBLYMAN HAYDEN: Did it have any further authority 
'
1
! than that? 
4 p 
DR. BOOK: Not that I know of. 
ASSEMBLYMAN HAYDEN: Was that passed on to either Mr. 
6 
Warriner or to the Scientific Advisory Panel? 
7 
DR. BOOK: It wasn't passed on to the Scientific 
8 
Advisory Panel. It was passed on to Mr. Warriner and to the 
9 
members of the interagency steering group. 
10 
ASSEMBLYMAN HAYDEN: Did you get a reply to that from 
I 1 
any member of the interagency working group? 
12 




ASSEMBLYMAN HAYDEN: Did you have conversations with --
15 
there were people who said: Nice memo? 
16 
DR. BOOK: Yes. 
17 
ASSEMBLYMAN HAYDEN: Who for instance from the 
I 8 
interagency groups said that it was a good memo? 
19 








DR. BOOK: No. 
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ASSEMBLYMAN HAYDEN: He re as your "ethical" to 
memo. D that did that at least as 
7 
8 
you heard the term? 
9 
DR. BOOK: I th because I thought that we were 
10 
justified in at least was my position as the author of that 
!! 
11 li 'i II 
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ASSEMBLYMAN HAYDEN: Did know that in Proposition 65 
in if reference is made codes are re 
to an 1 were not s on scientific 
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ASSEMBLYMAN You knew at time? 
23 
DR. BOOK: I don't reca 1 exact the citation. Oh, I 
24 
don t if I 
25 
ASSEMBLYMAN Would s calling it an 
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Did you call Dr. Book's memo the "ethical" memo? 
MR. WARRINER: He has a phrase in there where he 
suggested it's important to give public notice, public 
information, and he felt that it was an ethical duty to let the 
public know of the concerns that we had. 
That's one of the reasons why we chose the two-list 
approach so the public would have full knowledge of all the 
chemicals we were concerned with. 
ASSEMBLYMAN HAYDEN: So you called it an "ethical" memo 
because 
MR. WARRINER: He used the term. He felt there was an 
ethical obligation to advise the public. 
ASSEMBLYMAN HAYDEN: I thought that Dr. Book just said 
that you called it the "ethical" memo. 
MR. WARRINER: I did, too. 
ASSEMBLYMAN HAYDEN: And you called it the "ethical" 
memo because he was recommending that the process be open to the 
public? 
MR. WARRINER: No, no, no, no. 
What he said was that the public should be made aware of 
all the chemicals that we were concerned about. That was the 
reason for the primary and secondary, or candidate, list, was to 
let the public know all the chemicals that the Panel's focused 
on. 
ASSEMBLYMAN HAYDEN: So in call it an "ethical" memo, 
you didn't imply that it was ethical as opposed to your 
conclusions and recommendations? 
80 
MR. WARRINER: No, I wouldn't put it that way, sir. 
ASSEMBLYMAN HAYDEN: It wasn't the right thing to do as 
opposed to were t to ? 
MR. WARRINER: No, I wouldn't put it that way either. 
(Laughter.) 
ASSEMBLYMAN HAYDEN: I have no other questions. 
CHAIRMAN TORRES: At any time did you or anyone 
8 associated with recommendations, you Counsel, or you Mr. 














General's office, or a telephone conversation with one of your 
friends in the AG's office regarding the interpretation of this 
MR. WARRINER: We d not request an opinion either 
14 
informal or formal. 
15 
CHAIRMAN TORRES: You never picked up the phone and 
16 
said, " , or you may be out there, what do you 
17 
think about is issue? We're try to compare notes. 11 
18 






CHAIRMAN TORRES: Counsel, d you at any time? 








CHAIRMAN TORRES: You fe you were fully competent to 
analyze this Init ive? 
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presented from a variety of sources, and we saw those. And we 
prepared our own analysis, s. 
CHAIRMAN TORRES: At no time d you compare notes of 







lj with any 








)! MR. TOUSIGNANT: We discussed the Attorn 
4 General's office matters of representation, of course, but --
5 CHAIRMAN TORRES: Matters of representation. This was 
6 after the list was issued or prior to its issuance? 
7 MR. WARRINER: Might have been the day before. 
8 CHAIRMAN TORRES: Might have been the day before when 
9 you told him that you were going to come out with a shorter list 
10 than you had anticipated or than others had anticipated? 
l 1 
MR. WARRINER: Well, actually, there were other people 
12 
who argued the list should have been four chemicals, or no 
13 
chemicals, and there were other people arguing we ought to have 
14 
' 26 7 chf~micals. But when it became clear that we were going to 
15 
issue list that was going to get us into court, either the long 
16 
or the short, depending on how you want to look at it, approach, 
17 
we contacted the Attorney General's office and discussed that. 
18 
CHAIRMAN TORRES: This is speaking procedurally, are 
19 
there times when you, Counsel, would deal with the Attorney 
20 
General's office to compare notes on issues that come before you? 
21 





CHAIRMAN TORRES: All right. 
25 
The reference, for your own , the reference 
26 
that Mr. Hayden was referring to which cites the Labor Code 
27 




which might have g some light to your analysis in terms of 
2 
deal list espec 1 as related to those other 
3 
areas that we di ssed 
4 
Any st s? Senator Greene. 
5 
SENATOR GREENE: On po ' I that Mr. 
6 
Warriner the Counsel stated was no reference to 
7 
animals. Now comes out var s sections of code, 
8 
or in one or two sections of , animals are mentioned. 
" .: 
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SENATOR GREENE: Now, those sections of code are 
specifical the Initiative. And you just refe 
testified was there reference to 
animals. 
So now, wh is , sir. ? It can't 
MR. WARRINER is no ment of animals in the 
word of In 
16 
17 
SENATOR GREENE: Yes, it re s a specific code 
] 8 
' wh s , if it's know, it's s an o, 
19 
re spec if sect of should, it seems to 
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California. So the documents they had in front of them was the 
Initiative and the --
SENATOR GREENE: But 1 1 , if specific 
sections of code ure included within the Initiative, that is 
included. Legally. You don't have to be a lawyer to know that. 
All you have to know is the structure of law. 
MR. WARRINER: The question was, did it mention animals 
or humans, and it only refers to humans in the Initiative itself. 
SENATOR GREENE: But the code mentions animals, sir. 
MR. WARRINER: Right, the code also mentions the other 
references, and it's those references themselves that create the 
ambiguity. 
SENATOR GREENE: I'll bet you in court your argument 
won't stand up. 
CHAIRMAN TORRES: I guess we understand what voters have 
in their possession on election day, and sometimes we don't feel 
that's enough either, or maybe some cases it may be too much. 
However, you and I have a higher duty and a higher 
responsibility. And that higher duty requires us, mandates us by 
law and by moral obligat , to make sure that we examine an 
initiative in all of its as ts. And if a code section is 
referenced, then reference ought to be incorporated within 
standards that we pursue. 
And I think you know that, Mr. Warriner. 
MR. WARRINER: It is. 

















ASSEMBLYMAN HAYDEN: I point out further that if 
he shifts the irman, to the ballot argument as , Mr 
opposed to 1 says In s 
that the IARC list and NTP list luded. So it's 11 
fairly clear 1 were about. 
I th is 
MR. WARRINER: is, of course, over what 
8 
part of the IARC and NTP lists are included. 
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You asked earl what now becomes of these Department 
12 
of Health Service gu lines? 
13 
CHAIRMAN TORRES: Yes, we have. 
14 
ASSEMBLYMAN HAYDEN: They seem to be at odds now with 
15 
the new State 
16 
CHAIRMAN TORRES: Well, 's understanding those 
17 
guidel will to if Panel to 
18 
as of r rev ss. 
Isn t correct? 
19 
20 
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ASSEMBLYMAN HAYDEN: Does that mean that you're 
recommending that these guidelines, these DHS guidelines, which 
are roughly equ lent to IARC and NTP lists, be adopted as 
part of the minimal list by the Scientific Review Panel? 
MR. WARRINER: You're asking two questions. First of 
all, the Panel has to select a procedure. 
ASSEMBLYMAN HAYDEN: All right. 
MR. WARRINER: It could select Health Services; it could 
select IARC itself which is very close; it could select the EPA 
which is slightly different, or the NTP program. 
After they've selected the policy, then they have to 
decide whether all, some, what part of the chemicals that were 
reviewed by e s body that initiated the 
procedures should be luded on the Panel's list of chemicals. 
It's a two-fold process. 
ASSEMBLYMAN HAYDEN: Maybe I'm missing something, but if 
they're not going to do or 1 research, this Panel --
MR. WARRINER: Correct. 
ASSEMBLYMAN HAYDEN: If they adopt one of these long 
lists in 250 range as va 1 what more do they 
have to do with respect to this debate over a short list versus 
long list? 
MR. WARRINER: What they do is adopt a policy which says 
how they're going to view carcinogens. And then they look at 
what the group that or that pol y found to be the 
applicability of that pol y to chemicals. And then they decide 
whether the policy was correctly applied or not, and that helps 
them decide which of those als go on the primary list. 
86 
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MR. WARRINER: yes. 
10 
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11 
going to se rock-bottom lists are wrong? 
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MR. WARRINER: No. That's up to them. 
The Governor was quite clear that the Governor's Office 
is no longer involved. The Panel itself reviews the chemicals 
and makes a decision about moving them on to the list. 
ASSEMBLYMAN HAYDEN: Are you calling the scientists to 
testify who are the authors of the aforementioned policies and 
protocols, IARC, NTP? 
MR. WARRINER: I think what Dr. Book has done is 
provided copies of each of those to the Panel with the 
anticipation that they would, before the meeting, read them and 
become familiar with them, and then discuss among themselves 
which ones they think should be the policy under which this Panel 
operates. 
The IARC arrangement's pretty much the same as the 
Health Services' guidelines in terms of the list. 
CHAIRMAN TORRES: Thank you very much, gentlemen. 
MR. WARRINER: Thank you. 
CHAIRMAN TORRES: Sarah Reusswig who is the Program 
Analyst for the Legislative Budget Committee. 
Welcome to the Committee. 
MS. REUSSWIG: Thank you very much, Senator. 
My name's Sarah Reusswig with the Legislative Analyst's 
Office. To my right is Carol Bingham, Principal Program Analyst 
for the Health Section. 
Our statement's going to be very brief because 
basically, given the state of the Governor's budget and the fact 
that we haven't received any further BCPs, there's really not 
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Our analysis of the Governor's proposal or of 
Propos ion 65 included three sections. F st of all, we 
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And then we evaluated what the State could do. Going 
8 
beyond that, we made some assumptions about, or looked at what 
9 
the State has done in the past in other areas of environmental 
10 
health concern, and carne up with some conclusions about what the 
ll 
State ought to do at the very least. 
12 
The Scientific Advisory Panel seems to be going in the 
13 
direction of addressing those concerns. What they ought to do at 
14 
the very least is provide some statewide kind of guidelines as to 
15 
what ought to be included, what shouldn't be included, so that 
16 I 
courts, as implement the Proposition, if that is in fact 
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Until we get some sort of budget proposal, however, we 
20 
have no basis on to tell you how much this is going to cost 
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We'd be happy to answer any questions you have. 
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SENATOR GREENE: I have a question. 
Well, it might not be fair to ask this of analysts, but 
Mr. Chair, let me po th out to you, and it's something I'm 

































I wonder if there's any connection in the Governor's 
desire to phase out Cal OSHA and the action that they've taken in 
the compliance with this? 
I mean, it might be reaching, but considering some of 
the other things going on, it might not be farfetched, because if 
you look at statements to comply an annual list, where it says 
chemicals that are regulated are carcinogens by the State 
Occupational Safety and Health Act, you do away with that, then 
you're left with federal. And federal's coverage in this area is 
minimal compared to the State's coverage in this area, even to 
notification of hazardous substance on the job, just advising 
workers that they're working with those kinds of substances. 
So it might not be too farfetched to think that there's 
an interconnection in this separate and apart from any separate 
desire relating to OSHA. 
I just throw that out because it seems like a strange 
coincidence. 
much. 
CHAIRMAN TORHES: Good point. 
Any other questions? 
All right, this hearing is adjourned. Thank you very 
(Thereupon this Joint Hearing on the 
Implementation of Proposition 65 was 
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